{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T21:05:36Z","timestamp":1768943136837,"version":"3.49.0"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/wfpe2805","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:01:38Z","timestamp":1761814898000},"page":"4264-4275","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effects of oxaliplatin-based versus irinotecan-based regimens combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases"],"prefix":"10.62347","volume":"15","author":[{"given":"Yingting","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2021.01.01","article-title":"Colorectal cancer burden and trends: comparison between China and major burden countries in the world","volume":"33","author":"Zhou","year":"2021","unstructured":"Zhou J, Zheng R, Zhang S, Zeng H, Wang S, Chen R, Sun K, Li M, Gu J, Zhuang G and Wei W. Colorectal cancer burden and trends: comparison between China and major burden countries in the world. Chin J Cancer Res 2021; 33: 1-10.","journal-title":"Chin J Cancer Res"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ai XN, Zhang Q, Jin CG, Hu H, Zhang WX, Wu ZY and Xiu DR. Relationship between hepatic surgical margins of colorectal cancer liver metastases and prognosis: a review. Medicine (Baltimore) 2024; 103: e37038.","DOI":"10.1097\/MD.0000000000037038"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.7150\/jca.46155","article-title":"Nomograms predicting overall survival and cancer-specific survival for synchronous colorectal liver-limited metastasis","volume":"11","author":"Li","year":"2020","unstructured":"Li Y, Liu W, Zhao L, G&#xFC;ng&#xF6;r C, Xu Y, Song X, Wang D, Zhou Z, Zhou Y, Li C, Pei Q, Tan F and Pei H. Nomograms predicting overall survival and cancer-specific survival for synchronous colorectal liver-limited metastasis. J Cancer 2020; 11: 6213-6225.","journal-title":"J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12967-024-05994-y","article-title":"Mfsd2a suppresses colorectal cancer progression and liver metastasis via the S100A14\/STAT3 axis","volume":"23","author":"Sun","year":"2025","unstructured":"Sun L, Li X, Xiao Y, Yu W, Chen X, Wang Z, Xia N, Chen X, Chen M, Zhu H, Li J, Wei J, Han S and Pu L. Mfsd2a suppresses colorectal cancer progression and liver metastasis via the S100A14\/STAT3 axis. J Transl Med 2025; 23: 59.","journal-title":"J Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3390\/cancers13061371","article-title":"Review of intra-arterial therapies for colorectal cancer liver metastasis","volume":"13","author":"Kwan","year":"2021","unstructured":"Kwan J and Pua U. Review of intra-arterial therapies for colorectal cancer liver metastasis. Cancers (Basel) 2021; 13: 1371.","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1097\/JS9.0000000000000709","article-title":"Clinicopathological features and prognosis of synchronous and metachronous colorectal cancer: a retrospective cohort study","volume":"109","author":"Fan","year":"2023","unstructured":"Fan H, Wen R, Zhou L, Gao X, Lou Z, Hao L, Meng R, Gong H, Yu G and Zhang W. Clinicopathological features and prognosis of synchronous and metachronous colorectal cancer: a retrospective cohort study. Int J Surg 2023; 109: 4073-4090.","journal-title":"Int J Surg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-022-00286-9","article-title":"Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress","volume":"10","author":"Marx","year":"2022","unstructured":"Marx C, Sonnemann J, Maddocks ODK, Marx-Bl&#xFC;mel L, Beyer M, Hoelzer D, Thierbach R, Maletzki C, Linnebacher M, Heinzel T and Kr&#xE4;mer OH. Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer Metab 2022; 10: 10.","journal-title":"Cancer Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jpp\/rgae060","article-title":"GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition","volume":"76","author":"Chen","year":"2024","unstructured":"Chen H, Yang F, Zhao Q, Wang H, Zhu M, Li H, Ge Z, Zhang S, Guo Q and Hui H. GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition. J Pharm Pharmacol 2024; 76: 1006-1017.","journal-title":"J Pharm Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12885-023-11139-z","article-title":"Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study","volume":"23","author":"Fang","year":"2023","unstructured":"Fang X, Zhong C, Weng S, Hu H, Wang J, Xiao Q, Wang J, Sun L, Xu D, Liao X, Dong C, Zhang S, Li J, Ding K and Yuan Y. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. BMC Cancer 2023; 23: 676.","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3390\/pharmaceutics15102411","article-title":"Targeting lactate dehydrogenase-B as a strategy to fight cancer: identification of potential inhibitors by in silico analysis and in vitro screening","volume":"15","author":"Vlasiou","year":"2023","unstructured":"Vlasiou M, Nicolaidou V and Papaneophytou C. Targeting lactate dehydrogenase-B as a strategy to fight cancer: identification of potential inhibitors by in silico analysis and in vitro screening. Pharmaceutics 2023; 15: 2411.","journal-title":"Pharmaceutics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JHC.S398632","article-title":"Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram","volume":"10","author":"Su","year":"2023","unstructured":"Su K, Huang W, Li X, Xu K, Gu T, Liu Y, Song J, Qian K, Xu Y, Zeng H, Yang Y, Guo L and Han Y. Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma 2023; 10: 69-79.","journal-title":"J Hepatocell Carcinoma"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12957-023-03108-4","article-title":"Evaluation of multiple biological indicators for the combined diagnosis of metastases from colorectal cancer-a retrospective study based on 1163 patients","volume":"21","author":"Chen","year":"2023","unstructured":"Chen B, Zhou J, Ma Y, Sun Q, Ren J and Wang D. Evaluation of multiple biological indicators for the combined diagnosis of metastases from colorectal cancer-a retrospective study based on 1163 patients. World J Surg Oncol 2023; 21: 229.","journal-title":"World J Surg Oncol"},{"key":"ref12","unstructured":"Wang J, Sun Q, Zhao J, Li Z, Kou D and Qu D. Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis. J BUON 2021; 26: 93-100."},{"key":"ref13","unstructured":"National Health Commission of the People&#x2019;s Republic of China. Diagnosis and Treatment Guidelines for Colorectal Cancer in China (2020 Edition). Chin J Surg 2020; 58: 561-585."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"1)","volume":"45","author":"Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2125.1978.tb01676.x","article-title":"Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment","volume":"6","author":"Maxwell","year":"1978","unstructured":"Maxwell C. Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br J Clin Pharmacol 1978; 6: 15-24.","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Vitorino DF de M, Martins FLM, Souza A de C and Prado GF. Utilizao do SF-36 em ensaios cl&#xED;nicos envolvendo pacientes fibromi&#xE1;lgicos: determinao de crit&#xE9;rios m&#xED;nimos de melhora cl&#xED;nica. Rev Neuroci&#xEA;nc 2019; 12: 147-151.","DOI":"10.4181\/RNC.2004.12.147"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","unstructured":"Tang W, Ren L, Liu T, Ye Q, Wei Y, He G, Lin Q, Wang X, Wang M, Liang F, Cui Y and Xu J. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial. J Clin Oncol 2020; 38: 3175-3184.","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jamaoncol.2024.5174","article-title":"First-line systemic treatment for initially unresectable colorectal liver metastases: post hoc analysis of the CAIRO5 randomized clinical trial","volume":"11","author":"MJG","year":"2025","unstructured":"Bond MJG, Bolhuis K, Loosveld OJL, de Groot JWB, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MSL, Rijken AM, Verhoef C, de Wilt JHW, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MRW, van Lienden KP, Hermans JJ, Molenaar IQ, Gr&#xFC;nhagen DJ, de Valk B, Haberkorn BCM, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, Komurcu A, May AM, Swijnenburg RJ and Punt CJA; Dutch Colorectal Cancer Group. First-line systemic treatment for initially unresectable colorectal liver metastases: post hoc analysis of the CAIRO5 randomized clinical trial. JAMA Oncol 2025; 11: 36-45.","journal-title":"JAMA Oncol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yu B, Wang Y, Bing T, Tang Y, Huang J, Xiao H, Liu C and Yu Y. Platinum prodrug nanoparticles with COX-2 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer. Adv Mater 2024; 36: e2310456.","DOI":"10.1002\/adma.202310456"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","unstructured":"Ribatti D. Immunosuppressive effects of vascular endothelial growth factor. Oncol Lett 2022; 24: 369.","journal-title":"Oncol Lett"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Aranda E, Vi&#xE9;itez JM, G&#xF3;mez-Espa&#xF1;a A, Gil Calle S, Salud-Salvia A, Gra&#xF1;a B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, Gonz&#xE1;lez-Flores E, Salgado Fern&#xE1;ndez M, Guill&#xE9;n-Ponce C, Garcia-Carbonero R, Safont MJ, La Casta Munoa A, Garc&#xED;a-Paredes B, L&#xF3;pez L&#xF3;pez R, Sastre J and D&#xED;az-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and &#x2265; 3 circulating tumour cells: the randomised phase III VISN&#xDA;-1 trial. ESMO Open 2020; 5: e000944.","DOI":"10.1136\/esmoopen-2020-000944"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"189079","DOI":"10.1016\/j.bbcan.2024.189079","article-title":"VEGF signaling: role in angiogenesis and beyond","volume":"1879","author":"Shaw","year":"2024","unstructured":"Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P and Rao G. VEGF signaling: role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer 2024; 1879: 189079.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhu D, Yu Y, Chang W, Ye L, Feng Q, Xu P, Chen M, Ji M, Wei Y, Liu T and Xu J. VIC regimen (vemurafenib\/irinotecan\/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated unresectable or metastatic colorectal cancer in asian patients: a prospective cohort study. Clin Colorectal Cancer 2024; 23: 354-363, e4.","DOI":"10.1016\/j.clcc.2024.05.006"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2174\/0118715206294297240805073550","article-title":"Molecular imaging of melanoma vegf-expressing tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab)","volume":"24","author":"Camacho","year":"2024","unstructured":"Camacho X, Perroni C, Alfaya L, Cabrera M, Tassano M, Garc&#xED;a MF, Fern&#xE1;ndez M, Reyes AL, Paolino A, Savio E, Cerecetto H, Cabral P and Gambini JP. Molecular imaging of melanoma vegf-expressing tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab). Anticancer Agents Med Chem 2024; 24: 1347-1359.","journal-title":"Anticancer Agents Med Chem"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.4240\/wjgs.v15.i5.906","article-title":"Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer","volume":"15","author":"YL","year":"2023","unstructured":"Jiang YL, Fu XY and Yin ZH. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. World J Gastrointest Surg 2023; 15: 906-916.","journal-title":"World J Gastrointest Surg"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41416-024-02908-z","article-title":"Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma","volume":"132","author":"Deng","year":"2025","unstructured":"Deng M, Zhao R, Zou H, Guan R, Wang J, Lee C, He B, Zhou J, Li S, Wei W, Cai H and Guo R. Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma. Br J Cancer 2025; 132: 371-383.","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1740774520959313","article-title":"Adverse event load, onset, and maximum grade: a novel method of reporting adverse events in cancer clinical trials","volume":"18","author":"Lopes","year":"2021","unstructured":"Lopes GS, Tournigand C, Olswold CL, Cohen R, Kempf E, Saltz L, Goldberg RM, Hurwitz H, Fuchs C, de Gramont A and Shi Q. Adverse event load, onset, and maximum grade: a novel method of reporting adverse events in cancer clinical trials. Clin Trials 2021; 18: 51-60.","journal-title":"Clin Trials"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","unstructured":"Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Jiang X, Liu J, Zhao H, Pierce WF, Mehta S, Goldberg KB, Theoret MR, Kluetz PG, Pazdur RB and Lemery SJ. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res 2021; 27: 1836-1841.","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/10\/ajcr0166398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:48:58Z","timestamp":1768895338000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/10\/ajcr0166398.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wfpe2805","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}